RxDoctor Payments Data

Joseph Neilitz, DO

Ophthalmology · Menasha, WINPI 1043473234

Payments from drug & device makers

$1,255in general payments, 2019–2025

Across 20 payments — averaging $62.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Carl Zeiss Meditec USA, Inc.$768
  • Alcon$140
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$124
  • AbbVie$93
  • Apellis Pharmaceuticals, Inc.$42
  • Sun Pharmaceutical Industries Inc.$28
  • plus $60 from 3 others

What the payments were for

  • Travel & lodging$76861%
  • Food & beverage$48639%

General payments by program year

19
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,255 in reported general payments places this provider in the 65th percentile of 337 ophthalmology providers in Wisconsin.

See all ophthalmology providers in Wisconsin

Medicare billing

Part B allowed, 2024
$402,866
Medicare patients
442
Services billed
2,317

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast60$72,112
RestasisCyclosporine76$60,013
Cyclosporine55$24,981
IlevroNepafenac39$20,297
ProlensaBromfenac Sodium36$12,916
Bromfenac Sodium55$12,203
Prednisolone Acetate228$8,971
LumiganBimatoprost12$7,450
Loteprednol Etabonate44$6,141
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol29$5,343
Latanoprost386$5,002
MoxifloxacinMoxifloxacin Hcl127$4,471
Travoprost18$1,738
Timolol Maleate91$1,631
Ketorolac Tromethamine39$1,330

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$93$67,46388 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCProlensa, Loteprednol Etabonate$124$19,05680 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 337 ophthalmology providers in Wisconsin.

Other ophthalmology in Menasha

See the full list for Wisconsin

Where these figures come from

Is this you, or does something look wrong? →